About us
Amarna’s next-generation viral vector platform promises to transform treatment across many disease areas."

Amarna in brief

Amarna Therapeutics is a privately held European biotechnology company developing a next-generation viral vector platform that could play a key role in transforming treatment across many disease areas.

Amarna is the first company to successfully develop SVac, a viral vector platform derived from the simian polyomavirus 40 (SV40). Amarna produces SVac vector particles using its proprietary SuperVero producer cell line.

One of the key factors that has held back the biologics revolution has been the development of efficient delivery systems. Viral vectors, and more specifically SV40-based delivery platforms, have looked to be the best approaches but prior to Amarna, no one has been able to develop a viable production system.

Unlike other delivery systems, SVac is non-immunogenic, delivers to a broad range of cell types and tissues, and can be produced in large quantities. Consequently, it offers significant advantages over other viral vectors which are inefficient, immunogenic and are difficult to produce in the quantities needed for commercialization.

For patients, SVac-based therapeutics means a paradigm shift. A single SVac administration provides long-lasting treatment effects compared with current treatment schedules.

Besides SVac, Amarna has a second innovative production platform, PRP3, which is a cost-effective and high-yielding platform to produce therapeutic proteins.

Amarna Therapeutics B.V. was founded in 2008 and is headquartered in Leiden, the Netherlands, with R&D and production facilities in the Netherlands and Spain.